Prevention of Seasonal Affective Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00046241|
Recruitment Status : Completed
First Posted : September 25, 2002
Last Update Posted : January 23, 2017
|Condition or disease||Intervention/treatment||Phase|
|Seasonal Affective Disorder||Drug: Extended-release bupropion hydrochloride||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A 7 Month, Multicenter, Randomized, Double-blind, Placebo-controlled Comparison of 150-300mg/Day of Extended-release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Affective Disorder in Subjects With a History of Seasonal Affective Disorder Followed by an 8-week Observational Follow-up Phase|
|Actual Study Start Date :||September 2002|
|Actual Primary Completion Date :||June 2003|
|Actual Study Completion Date :||June 2003|
- Time between randomization and onset of a seasonal depressive episode. Proportion of depression-free subjects.
- Change in HAMD-24 and -17 total score. Change in pain score.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00046241
|Study Director:||GSK Clinical Trial, MD||GlaxoSmithKline|